Latest Stemline Therapeutics Inc. Stories

2011-06-06 07:00:00

NEW YORK, June 2, 2011 /PRNewswire/ -- Stemline Therapeutics, Inc. today announced that clinical results from a multi-epitope brain cancer vaccine, that Stemline has licensed from the University of Pittsburgh (Pitt) and is further developing as SL-701, will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL, on Monday, June 6, 2011 at 1 PM CT. Dr. Hideho Okada, Associate Professor of Neurological Surgery at Pitt, will deliver the presentation....

2011-03-09 07:30:00

NEW YORK, March 9, 2011 /PRNewswire/ -- Stemline Therapeutics, Inc. today announced that SL-401, the Company's lead compound, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML). SL-401 has completed a multi-center Phase I/II clinical trial in AML where it has demonstrated single agent efficacy, including two durable complete responses (CRs), multiple blast reductions and disease stabilizations, and an...

Word of the Day
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'